Loading company…
Renerval Biotherapeutics develops blood cell products and regenerative medicine using iPSC technology.
Founded in 2021 and based in Shanghai, Renerval Biotherapeutics is developing artificial blood products and cell therapies using iPSC technology, including regenerated platelets and red blood cells. Its research covers cancer treatment, blood disorders, surgery, and emergency care. In August 2026, it raised CNY 150 million in pre-Series A funding from Efung Capital, Shanghai Minhang Financial Investment Development, Shunwei Capital, and other investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in